SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences surges on the BSE

28 Apr 2025 Evaluate

Zydus Lifesciences is currently trading at Rs 879.35, up by 20.25 points or 2.36% from its previous closing of Rs 859.10 on the BSE.

The scrip opened at Rs 860.05 and has touched a high and low of Rs 880.40 and Rs 860.05 respectively. So far 6364 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1323.90 on 09-Aug-2024 and a 52-week low of Rs 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs 886.80 and Rs 830.05 respectively. The current market cap of the company is Rs 88342.31 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.

United States Food and Drug Administration (USFDA) has concluded surveillance inspection at Zydus group’s API Unit, located at Dabhasa in Gujarat. The inspection was conducted from April 21 to 25, 2025. The inspection concluded with 6 observations and none of them were related to Data Integrity. The company is confident to address the observations expeditiously. 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

1150.50 -9.35 (-0.81%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: